Table 2.
Patient demographics and clinical characteristics.
| Patient Characteristics | Data |
|---|---|
| Total number of patients with PCa included | 86 |
| Age (years), mean ± σ | 66.10 ± 8.13 |
| Comorbidities n (%) | 63 (73) |
| Arterial hypertension | 38 (44) |
| Diabetes Mellitus | 19 (22) |
| Tobacco | 13 (15) |
| PSA (ng/mL), median (IQR) | 7.4 (10.6–4.7) |
| Prostate volume (ml), median (IQR) | 43.5 (58–33) |
| Lesion size (mm), median (IQR) | 10 (15.8–8.0) |
| PSA-D MR (ng/mL2), median (IQR) | 0.15 (0.26–0.10) |
| Localization n (%) | |
| Transition Zone (TZ) | 5 (6) |
| Peripherical Zone (PZ) | 81 (94) |
| PI-RADS n (%) | |
| 3 | 2 (2) |
| 4 | 60 (70) |
| 5 | 24 (28) |
| Gleason Score n (%) | |
| 6 | 20 (23) |
| 7 (3 + 4) | 28 (33) |
| 7 (4 + 3) | 21 (33) |
| 8 | 5 (6) |
| 9 | 12 (14) |
σ = standard deviation; PSA = prostate-specific antigen; IQR = interquartile range; PCa = prostate cancer: PSA-D MR = prostate-specific antigen density by magnetic resonance.